BR9807887A - Complexos de estabilizados quanto à atividade e imobilizados de antagonistas de lhrh e processo para a sua preparação. - Google Patents

Complexos de estabilizados quanto à atividade e imobilizados de antagonistas de lhrh e processo para a sua preparação.

Info

Publication number
BR9807887A
BR9807887A BR9807887-9A BR9807887A BR9807887A BR 9807887 A BR9807887 A BR 9807887A BR 9807887 A BR9807887 A BR 9807887A BR 9807887 A BR9807887 A BR 9807887A
Authority
BR
Brazil
Prior art keywords
poly
cetrorelix
complexes
amino acids
lhrh antagonists
Prior art date
Application number
BR9807887-9A
Other languages
English (en)
Other versions
BR9807887B1 (pt
Inventor
Juergen Engel
Wolfgang Deger
Thomas Reissmann
Guenter Losse
Wolfgang Naumann
Sandra Murgas
Original Assignee
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Ag filed Critical Asta Medica Ag
Publication of BR9807887A publication Critical patent/BR9807887A/pt
Publication of BR9807887B1 publication Critical patent/BR9807887B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Patente de Invenção: <B>"COMPLEXOS DE ESTABILIZADOS QUANTO à ATIVIDADE E IMOBILIZADOS DE ANTAGONISTAS DE LHRH E PROCESSO PARA A SUA PREPARAçãO''<D>. No contexto dessa invenção, deve ser desenvolvido um sistema de retardo para antagonistas de LHRH, especialmente para Cetrorelix, por complexação com suportes biófilos adequados, que permite liberar de maneira dirigida a substância ativa durante várias semanas. Foram escolhidos os poli-aminoácidos ácidos poli-ácido glutâmico e poli-ácido asparagínico para a complexação com Cetrorelix. Os complexos de Cetrorelix-poli-aminoácido são preparados a partir de soluções aquosas por reunião das soluções e precipitação dos complexos, os quais, a seguir, são removidos por centrifugação e são secos, no vácuo, sobre P~ 2~O~ 5~. Se os complexos devem ser obtidos com composição definida, então, a liofilização deu bons resultados como método adequado. Os complexos de cetrorelix-ácido carboxílico foram preparados igualmente a partir das soluções aquosas. Os poli-aminoácidos ácidos poli-Glu e poli-Asp mostraram, no sistema de liberação estático, boas propriedades de retardo em função da hidrofobicidade e da massa molecular dos poli-aminoácidos. No teste com animais pode ser detectada a eficácia inicial dos complexos de Cetrorelix-poli-aminoácidos como sistema de depot. Assim, conseguiu-se alcançar, por complexação de Cetrorelix com poli-aminoácidos, uma supressão de testosterona em ratos machos durante 600 horas. Nesse caso, pode ser controlada a liberação de substância de ativa pelo tipo e pela massa molecular dos polímeros.
BRPI9807887-9A 1997-03-26 1998-03-11 complexos de estabilizados quanto à atividade e imobilizados de antagonistas de lhrh, processo para preparação de preparados de hormÈnio de peptìdeo a partir dos referidos complexos, bem como medicamentos que os contêm. BR9807887B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19712718A DE19712718C2 (de) 1997-03-26 1997-03-26 Immobilisierte und aktivitätsstabilisierte Komplexe von LHRH-Antagonisten und Verfahren zu deren Herstellung
PCT/EP1998/001398 WO1998042381A1 (de) 1997-03-26 1998-03-11 Immobilisierte und aktivitätsstabilisierte komplexe von lhrh-antagonisten und verfahren zu deren herstellung

Publications (2)

Publication Number Publication Date
BR9807887A true BR9807887A (pt) 2000-02-22
BR9807887B1 BR9807887B1 (pt) 2010-05-18

Family

ID=7824698

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9807887-9A BR9807887B1 (pt) 1997-03-26 1998-03-11 complexos de estabilizados quanto à atividade e imobilizados de antagonistas de lhrh, processo para preparação de preparados de hormÈnio de peptìdeo a partir dos referidos complexos, bem como medicamentos que os contêm.

Country Status (27)

Country Link
US (2) US6022860A (pt)
EP (1) EP0981377B1 (pt)
JP (1) JP4180120B2 (pt)
CN (1) CN1150943C (pt)
AR (1) AR012186A1 (pt)
AT (1) ATE249245T1 (pt)
AU (1) AU747808B2 (pt)
BR (1) BR9807887B1 (pt)
CA (1) CA2285054C (pt)
CZ (1) CZ300755B6 (pt)
DE (2) DE19712718C2 (pt)
DK (1) DK0981377T3 (pt)
ES (1) ES2206912T3 (pt)
HK (1) HK1025255A1 (pt)
HU (1) HUP0002059A3 (pt)
IL (1) IL131181A (pt)
NO (1) NO327404B1 (pt)
NZ (1) NZ337343A (pt)
PL (1) PL190090B1 (pt)
PT (1) PT981377E (pt)
RU (1) RU2207151C2 (pt)
SK (1) SK284461B6 (pt)
TR (1) TR199902168T2 (pt)
TW (1) TW520288B (pt)
UA (1) UA69381C2 (pt)
WO (1) WO1998042381A1 (pt)
ZA (1) ZA982225B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
EP0788799A3 (en) 1996-02-07 1998-10-21 ASTA Medica Aktiengesellschaft LHRH-Antagonists in the treatment of fertility disorders
US20070185032A1 (en) * 1996-12-11 2007-08-09 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US5968895A (en) 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
JP2002512975A (ja) * 1998-04-23 2002-05-08 アスタ メディカ アクチエンゲゼルシャフト 受精能力障害の治療薬
CO5160256A1 (es) * 1999-02-08 2002-05-30 Zentaris Ag Sales de peptidos farmaceuticamente activos para la liberacion sostenida y proceso de produccion
DE10024451A1 (de) * 2000-05-18 2001-11-29 Asta Medica Ag Pharmazeutische Darreichungsform für Peptide, Verfahren zu deren Herstellung und Verwendung
AU2001289079A1 (en) 2000-09-13 2002-03-26 Praecis Pharmaceuticals Incorporated Pharmaceutical compositions for sustained drug delivery
US20020169125A1 (en) * 2001-03-21 2002-11-14 Cell Therapeutics, Inc. Recombinant production of polyanionic polymers and uses thereof
AU2002322493A1 (en) * 2001-07-10 2003-01-29 Ams Research Corporation Surgical kit for treating prostate tissue
US7214662B2 (en) 2001-11-27 2007-05-08 Zentaris Gmbh Injectable solution of an LHRH antagonist
US8093207B2 (en) * 2005-12-09 2012-01-10 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products
WO2008083407A1 (en) 2007-01-02 2008-07-10 Aquabeam Llc Minimally invasive methods and devices for the treatment of prostate diseases
US9232959B2 (en) 2007-01-02 2016-01-12 Aquabeam, Llc Multi fluid tissue resection methods and devices
EP2259742B1 (en) 2008-03-06 2020-01-01 AquaBeam LLC Tissue ablation and cautery with optical energy carried in fluid stream
US9848904B2 (en) 2009-03-06 2017-12-26 Procept Biorobotics Corporation Tissue resection and treatment with shedding pulses
WO2010110455A1 (ja) * 2009-03-27 2010-09-30 国立大学法人 鹿児島大学 疎水化ポリアミノ酸からなるポリイオンコンプレックスとその用途
CN108606773B (zh) 2012-02-29 2020-08-11 普罗赛普特生物机器人公司 自动化图像引导的组织切除和处理
JP6403695B2 (ja) 2013-02-14 2018-10-10 プロセプト バイオロボティクス コーポレイション アクアアブレーションアクアビーム眼科手術方法および装置
JP6461971B2 (ja) 2013-09-06 2019-01-30 プロセプト バイオロボティクス コーポレイション 飛散パルスを用いた組織切除および処置
BR112016031037B1 (pt) 2014-06-30 2023-02-07 Procept Biorobotics Corporation Aparelho para ablação de tecido vascular
CN107072591B (zh) 2014-09-05 2021-10-26 普罗赛普特生物机器人公司 与靶器官图像的治疗映射结合的医师控制的组织切除

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE257197C (pt) *
US4341767A (en) * 1980-10-06 1982-07-27 Syntex Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
DD257197A1 (de) * 1987-01-28 1988-06-08 Univ Dresden Tech Verfahren zur herstellung von immobilisierten, in ihrer biologischen aktivitaet stabilisierten und in ihren pharmakologischen eigenschaften modifizierten insulinpraeparationen
US4801577A (en) * 1987-02-05 1989-01-31 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists
DD269785A1 (de) * 1988-02-08 1989-07-12 Univ Dresden Tech Verfahren zur herstellung von aktivitaetsstabilisierten und in ihren pharmakologischen eigenschaften modifizierten peptidderivaten
DD273980B5 (de) * 1988-07-12 1994-04-14 Berlin Chemie Ag Verfahren zur Herstellung von Insulin-Pr{paraten zur rektalen Anwendung
DK0454044T3 (da) * 1990-04-25 1996-04-22 Hoechst Ag Farmakologisk præparat indeholdende polyelektrolytkomplekser på mikropartikelform og mindst et virksomt stof
DD299265A5 (de) * 1990-09-11 1992-04-09 Technische Universitaet Dresden,De Verfahren zur herstellung von immobilisierten und aktivitaetsstabilisierten praeparaten des gonadotropin-releasing-hormons oder dessen analoga mit polyaminosaeuren
US5834520A (en) * 1992-10-08 1998-11-10 Asta-Medica Aktiengesellschaft Container for injectable mesna solutions
AU5605894A (en) * 1992-11-12 1994-06-08 Molecular Dynamics, Inc. Lipophilic peptide-based carriers for targeted drug delivery using rational drug-binding design
DE4305225A1 (de) * 1993-02-19 1994-08-25 Asta Medica Ag Neues Herstellverfahren für Cetrorelix Lyophilisat
US5449720A (en) * 1993-05-24 1995-09-12 Biotech Australia Pty Limited Amplification of the VB12 uptake system using polymers
US5502035A (en) * 1993-08-06 1996-03-26 Tap Holdings Inc. N-terminus modified analogs of LHRH
CA2178592C (en) * 1993-12-09 2009-07-28 Jurgen Engel Long-acting injection suspensions and a process for their preparation
US5821230A (en) * 1997-04-11 1998-10-13 Ferring Bv GnRH antagonist decapeptides

Also Published As

Publication number Publication date
NO327404B1 (no) 2009-06-22
SK131699A3 (en) 2000-05-16
BR9807887B1 (pt) 2010-05-18
CZ300755B6 (cs) 2009-08-05
DE59809575D1 (de) 2003-10-16
CN1150943C (zh) 2004-05-26
ZA982225B (en) 1998-04-03
IL131181A0 (en) 2001-01-28
DE19712718C2 (de) 1999-09-23
US6022860A (en) 2000-02-08
RU2207151C2 (ru) 2003-06-27
PT981377E (pt) 2004-02-27
PL335830A1 (en) 2000-05-22
JP2001520662A (ja) 2001-10-30
CA2285054C (en) 2007-08-21
SK284461B6 (sk) 2005-04-01
US6054555A (en) 2000-04-25
CN1249691A (zh) 2000-04-05
AU747808B2 (en) 2002-05-23
ES2206912T3 (es) 2004-05-16
HUP0002059A2 (hu) 2000-10-28
ATE249245T1 (de) 2003-09-15
EP0981377B1 (de) 2003-09-10
CA2285054A1 (en) 1998-10-01
DE19712718A1 (de) 1998-10-01
AR012186A1 (es) 2000-09-27
DK0981377T3 (da) 2003-11-10
UA69381C2 (uk) 2004-09-15
AU6920798A (en) 1998-10-20
NO994665D0 (no) 1999-09-24
JP4180120B2 (ja) 2008-11-12
WO1998042381A1 (de) 1998-10-01
NZ337343A (en) 2001-10-26
EP0981377A1 (de) 2000-03-01
CZ337199A3 (cs) 2000-03-15
TR199902168T2 (xx) 1999-12-21
HK1025255A1 (en) 2000-11-10
IL131181A (en) 2004-09-27
PL190090B1 (pl) 2005-10-31
NO994665L (no) 1999-09-24
TW520288B (en) 2003-02-11
HUP0002059A3 (en) 2001-02-28

Similar Documents

Publication Publication Date Title
BR9807887A (pt) Complexos de estabilizados quanto à atividade e imobilizados de antagonistas de lhrh e processo para a sua preparação.
PT1077688E (pt) Sistema terapeutico transdermico contendo pergolide
BR9607383A (pt) Composição farmacêutica útil para a transfecção de um ácido nucléico e utilização desta composição
KR20130087369A (ko) 양친매성 선형 펩티드/펩토이드 및 이를 포함하는 히드로겔
ATE541587T1 (de) Konjugat-additionsreaktionen zur kontrollierten abgabe von pharmazeutisch wirksamen substanzen
ATE453665T1 (de) Mage-a1 peptide die von klasse ii hla molekule presentiert werden
DE69730093D1 (de) Zubereitung mit verzögerter Freisetzung
BR9811264A (pt) Composições imunogênicas ao receptor de gastrina/cck-b e métodos para o tratamento de tumores
ATE272654T1 (de) Neue vernetzte derivate der hyaluronsäure.
BR9713404A (pt) ésteres de n-(aril/heteroarilacetil) aminoácidos, composições farmacêuticas compreendendo os mesmos, e métodos para a inibição da liberação de peptìdeo beta-amilóide e/ou de sua sìntese por uso de tais compostos.
BR0109266A (pt) Composto, composição farmacêutica, método de tratamento de um mamìfero afetado com um câncer, método de liberação de um composto nas células de um mamìfero afetado com um câncer e uso do composto
BRPI0115483B8 (pt) preparação de pantoprazol seco por congelação e injeção de pantoprazol
Grimmelikhuijzen et al. Isolation of< Glu-Leu-Leu-Gly-Gly-Arg-Phe-NH2 (Pol-RFamide), a novel neuropeptide from hydromedusae
CY1107729T1 (el) Φαρμακευτικες συνθεσεις
US3704282A (en) Catecholamine antigens and antibodies specific therefor
TR200103149T2 (tr) Virüs ve mikoplazmanın korunması için yöntemler
AU2383988A (en) Molecular decoyants and methods of use thereof
Jiang et al. Formaldehyde‐mediated aggregation of protein antigens: Comparison of untreated and formalinized model antigens
BR0009472A (pt) Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas
BR9506377A (pt) Peptídeo compreendendo uma subsequéncia de gp-39 hc proteina gp-39 hc ou peptideos composição farmacéutica uso da proteina gp-39 hc ou um ou mais dos peptídeos composição de diagnostico e processo de diagnóstico e kit de teste para a detecção de céçiças t auto-reativas ativadas
Jivan et al. Bio‐Orthogonal, Site‐Selective Conjugation of Recombinant Proteins to Microporous Annealed Particle Hydrogels for Tissue Engineering
PT81345B (pt) Processo para a preparacao de novos peptideos activos sobre o sistema nervoso central com accao sobre o sistema colinergico, e de composicoes farmaceuticas contendo estes compostos
DK87190A (da) Fremgangsmaade til at regulere plantevaekst under anvendelse af svovlholdige organiske syrer
Yang et al. Bioinspired Load‐Bearing Hydrogel Based on Engineered Sea Anemone Skin‐Derived Collagen‐Like Protein
DK0972032T3 (da) Peptider til behandling af systemisk lupus erythematosus

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Free format text: ZENTARIS AG (DE)

B25A Requested transfer of rights approved

Owner name: BLITZ F02-570 GMBH (DE)

Free format text: TRANSFERIDO POR FUSAO DE: ZENTARIS AG

B25D Requested change of name of applicant approved

Owner name: ZENTARIS GMBH (DE)

Free format text: ALTERADO DE: BLITZ F02-570 GMBH

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/05/2010, OBSERVADAS AS CONDICOES LEGAIS.

B24H Lapse because of non-payment of annual fees (definitively: art 78 iv lpi)
B15K Others concerning applications: alteration of classification

Ipc: A61K 38/09 (2006.01), A61K 47/64 (2017.0

B24F Patent annual fee: publication cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 24.8 NA RPI NO 2259 DE 22/04/2014 POR TER SIDO INDEVIDA.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE AS 13A, 14A, 15A, 16A, 17A, 18A, 19A, 20A, 21A E 22A ANUIDADES.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2607 DE 22-12-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.